Research on the Role of SLC1A5 in the Development of Esophageal Cancer

• Conditions: Esophageal Cancer; Amino Acid Transport Disorder
• Interventions: Other: SLC1A5 expression

• Registration Number: NCT02633436
• Lead Sponsor: Fourth Affiliated Hospital of Guangxi Medical University

Brief Summary

To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.

Detailed Description

This will be an observational study. The investigators will aim to enroll 100 male and female adult patients (aged 18 years and over) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for esophageal cancer.

The investigators will be using a standardized data collection form. This is an observational study in which standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent. An attempt will be made to see if there is a correlation between the expression of SLC1A5 with esophageal cancer.

Study Timeline

• Study Start: 2015-12
• Study First Submitted: 2015-12-06
• Study First Submitted QC: 2015-12-14
• Study First Posted: 2015-12-17
• Status Verified: 2016-08
• Last Update Submitted: 2016-08-11
• Last Update Posted: 2016-08-12
• Primary Completion: 2018-07
• Study Completion: 2018-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Patients with histologically proven esophageal cancer;
2. Age ≥18 years;
3. All patients must sign consent forms voluntarily;

Exclusion Criteria

1. Inability to obtain histologic proof of malignancy.
2. Age <18 years;

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
paired adjacent tissues	SLC1A5 expression	SLC1A5 expression of paired adjacent esophageal tissues from patients
cancer tissues	SLC1A5 expression	SLC1A5 expression of esophageal cancer tissues from patients

Primary Outcome Measures

Name	Time	Method
optical density (ODs) of each slice by immunohistochemistry assay	within one year (plus or minus 1 month) after surgery	For immunohistochemistry assay： Briefly, the samples will be cut into slices, which will be stained with standard steps. Finally, three high power fields will be randomly selected from each slice and the average optical density (OD) will be measured in each field.

Secondary Outcome Measures

Name	Time	Method
SLC1A5 expression detected by WesternBlot	within one year (plus or minus 1 month) after surgery	Western blot assay will be done by comparing the intensity of bands. To start with, xray film will be scanned on a flat-bed scanner. Then the grayscale image will be analyzed with software. Finally the Gray Value of each band will be obtained for analysis.

Trial Locations

Locations (2)

The Fourth Affiliated Hospital of Guangxi Medical University; 🇨🇳 Liuzhou, Guangxi, China

Liuzhou Maternity and Child Healthcare Hospital; 🇨🇳 Liuzhou, Guangxi, China